Leishmaniasis, a neglected tropical disease, is an epidemic and a public health concern in at least 98 countries. The currently available treatments impose several limitations, including high toxicity, reduced activity, and drug resistance, demanding a quest for novel and effective therapeutics. Since silver and gold-NHC complexes generally display promising biological applications evading drug resistance, in this research work, we have reported the synthesis, structures, structural characterizations, and in vitro antileishmanial activities of a novel series of Ag(I), Au(I), and Au(III) complexes of quinoxaline-wingtip N-heterocyclic carbene (NHC) ligands. The proligands and metal complexes were synthesized and fully characterized by using different spectroscopic techniques and solid-state single-crystal XRD analysis. All the synthesized complexes are investigated for their in vitro antileishmanial potential against intracellular amastigotes of different Leishmania species. Surprisingly, only Au(I) and Au(III)-NHC complexes are effective and display promising antileishmanial activity with IC 50 values varying between 0.3 and 17.5 μM. Structure–activity and toxicity relationships demonstrate the dicationic Au(III)-NHC complex encompassing the phenanthroline ligand as the lead candidate, exhibiting both a high activity and an excellent selectivity index (SI = 157), especially against L. amazonenis . These findings highlight the promising potential of these compounds as alternative therapeutic candidates for the treatment of leishmaniases.
No takes yet. Share an insight, caveat, or question.
Sahu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: